A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
A Phase 1, Multicenter, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of hSTC810 Monotherapy in Subjects With Advanced Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 02841
- Korea University Anam Hospital
-
Seoul, Korea, Republic of, 03722
- Yonsei University Severance Hospital
-
-
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Yale Cancer Center
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female aged at 18 ≥ years
- Capable and willing to give signed informed consent
- At least one measurable lesion as determined by RECIST Ver.1.1
- ECOG PS score ≤ 1
- Expected survival ≥ 12 weeks
- For female or male patients of reproductive potential: Agree to use contraception throughout the study and at least 6 months after the last dose.
Exclusion Criteria:
- Subject who has received anti-cancer treatment within 4 weeks prior to the first dose of study treatment.
- Subject who has received radiotherapy or major surgery within 4 weeks prior to screening.
- Any toxicity due to prior therapy that has not resolved to ≤ Grade 1 or returned to baseline by the time of starting study treatment.
- Subject with known severe (≥Grade 3) hypersensitivity to any checkpoint inhibitor.
- Clinically significant laboratory abnormalities.
- Subject with a history of another invasive malignancy within 3 years before the first dose of study drug.
- Subject with active central nervous system (CNS) metastases.
- Subject who requires high dose of steroids or other immunosuppressive medications.
- Subject with a history of autoimmune disease that has required systemic treatment in the past 2 years.
- Subject with active infection that requires systemic antimicrobial treatment.
- Subject with active HBV or HCV infection.
- Subject who has a known history of HIV infection.
- Subject with active tuberculosis.
- Subject with a documented history of a cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms consistent with NYHA Class IV within 6 months prior to screening.
- Subject with a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening CT scan.
- Subject who has received a prior allogeneic stem cell or solid organ transplant.
- Subject with a positive coronavirus disease (COVID) test during screening.
- Subjects who have received a live attenuated vaccine within 30 days prior to screening.
- Subject with another underlying medical condition.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: hSTC810
6 escalating doses of hSTC810 will be administered to participants
|
hSTC810 will be administered as an intravenous infusion (IV)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of DLTs
Time Frame: 4 weeks
|
Number and percentages of subjects with DLTs
|
4 weeks
|
|
Incidence of AEs, SAEs, and abnormalities in Lab
Time Frame: from signing ICF to 90 days after last dose
|
Number and percentages of subjects with Adverse Event, serious AEs, and abnormalities in lab parameters
|
from signing ICF to 90 days after last dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peak plasma concentration (Cmax)
Time Frame: Up to 2 years
|
Maximum plasma concentration of hSTC810 to evaluate the PK parameters
|
Up to 2 years
|
|
Minimum plasma concentration (Cmin)
Time Frame: Up to 2 years
|
Minimum blood plasma concentration of hSTC810 to evaluate the PK parameters
|
Up to 2 years
|
|
Time to maximum plasma concentration (Tmax)
Time Frame: Up to 2 years
|
Time to reach Cmax of hSTC810 to evaluate the PK parameters.
|
Up to 2 years
|
|
Area under the plasma concentration - time curve (AUC0-t)
Time Frame: Up to 2 years
|
AUC up to the last measurable concentration of hSTC810 to evaluate the PK parameters
|
Up to 2 years
|
|
Incidence of ADA
Time Frame: Up to 2 years
|
Number and percentages of subjects with positive ADAs
|
Up to 2 years
|
|
Objective response rate (ORR)
Time Frame: Up to 2 years
|
Percentage of participants with confirmed CR and confirmed PR determined by RECIST v1.1 and iRECIST
|
Up to 2 years
|
|
Best overall response (BOR)
Time Frame: Up to 2 years
|
the best response designation as determined by RECIST and iRECIST.
The BOR will be categorized as a CR, PR, SD, or PD
|
Up to 2 years
|
|
Clinical Benefit rate (CBR)
Time Frame: Up to 2 years
|
Percentage of Participants With confirmed CR, confirmed PR or SD with a duration of at least 6 months determined by RECIST v1.1 and iRECIST
|
Up to 2 years
|
|
Duration of response (DoR)
Time Frame: Up to 2 years
|
Time from initial response of confirmed CR or PR to disease progression or death determined by RECIST v1.1 and iRECIST
|
Up to 2 years
|
|
Progression free survival (PFS)
Time Frame: Up to 2 years
|
The period from the first dose to the documented disease progression or death determined by RECIST v1.1 or iRECIST
|
Up to 2 years
|
|
Overall survival (OS)
Time Frame: Up to 2 years
|
The period from first dose to the day of death from any cause.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Medical director, STCube, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STCUBE-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.